Braidwell LP Trims Stock Position in TransMedics Group, Inc. $TMDX

Key Points

• Braidwell LP reduced its holdings in TransMedics Group, Inc. by 7.3%, now owning 854,884 shares valued at approximately $57.5 million, making it the 20th largest position in their portfolio.
• TransMedics Group reported earnings of $0.92 per share, significantly exceeding analyst expectations of $0.48, along with quarterly revenue of $157.37 million.
• Analysts have varying views on TransMedics, with Morgan Stanley raising its price target from $115 to $123, while Wall Street Zen downgraded the stock from a "buy" to a "hold" rating.

Braidwell LP lessened its position in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 7.3% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 854,884 shares of the company's stock after selling 67,216 shares during the quarter. TransMedics Group comprises approximately 2.0% of Braidwell LP's portfolio, making the stock its 20th largest position. Braidwell LP owned about 2.53% of TransMedics Group worth $57,517,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the company. Smartleaf Asset Management LLC increased its holdings in TransMedics Group by 44.3% in the 1st quarter. Smartleaf Asset Management LLC now owns 440 shares of the company's stock valued at $30,000 after purchasing an additional 135 shares during the last quarter. CWM LLC increased its holdings in TransMedics Group by 20.1% in the 1st quarter. CWM LLC now owns 925 shares of the company's stock valued at $62,000 after purchasing an additional 155 shares during the last quarter. Campbell Newman Asset Management Inc. increased its holdings in TransMedics Group by 1.4% in the 1st quarter. Campbell Newman Asset Management Inc. now owns 11,619 shares of the company's stock valued at $782,000 after purchasing an additional 166 shares during the last quarter. Hager Investment Management Services LLC increased its holdings in TransMedics Group by 38.3% in the 1st quarter. Hager Investment Management Services LLC now owns 740 shares of the company's stock valued at $50,000 after purchasing an additional 205 shares during the last quarter. Finally, Nisa Investment Advisors LLC increased its holdings in TransMedics Group by 1.6% in the 1st quarter. Nisa Investment Advisors LLC now owns 15,824 shares of the company's stock valued at $1,065,000 after purchasing an additional 256 shares during the last quarter. Hedge funds and other institutional investors own 99.67% of the company's stock.

TransMedics Group Stock Down 0.0%

Shares of TMDX stock traded down $0.04 on Friday, reaching $104.01. 996,363 shares of the stock were exchanged, compared to its average volume of 1,307,980. The company has a current ratio of 9.86, a quick ratio of 9.17 and a debt-to-equity ratio of 1.61. The business's 50 day moving average price is $118.62 and its 200 day moving average price is $103.89. The company has a market capitalization of $3.55 billion, a price-to-earnings ratio of 53.89 and a beta of 2.18. TransMedics Group, Inc. has a twelve month low of $55.00 and a twelve month high of $169.29.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last issued its earnings results on Wednesday, July 30th. The company reported $0.92 EPS for the quarter, topping analysts' consensus estimates of $0.48 by $0.44. The firm had revenue of $157.37 million during the quarter, compared to the consensus estimate of $146.64 million. TransMedics Group had a net margin of 13.49% and a return on equity of 28.02%. The company's revenue was up 37.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.35 earnings per share. TransMedics Group has set its FY 2025 guidance at EPS. As a group, sell-side analysts expect that TransMedics Group, Inc. will post 1 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

TMDX has been the subject of several research reports. Needham & Company LLC restated a "hold" rating on shares of TransMedics Group in a research note on Monday, August 25th. Oppenheimer boosted their price target on shares of TransMedics Group from $130.00 to $150.00 and gave the stock an "outperform" rating in a research note on Tuesday, June 17th. Canaccord Genuity Group boosted their price target on shares of TransMedics Group from $129.00 to $142.00 and gave the stock a "buy" rating in a research note on Tuesday, July 15th. Wall Street Zen downgraded shares of TransMedics Group from a "buy" rating to a "hold" rating in a research note on Saturday, August 30th. Finally, Stifel Nicolaus initiated coverage on shares of TransMedics Group in a research note on Thursday. They issued a "hold" rating and a $115.00 price target for the company. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and four have assigned a Hold rating to the company's stock. Based on data from MarketBeat, TransMedics Group has an average rating of "Moderate Buy" and an average target price of $122.11.

Insider Activity at TransMedics Group

In related news, insider Anil P. Ranganath sold 686 shares of the business's stock in a transaction on Monday, June 9th. The shares were sold at an average price of $139.80, for a total transaction of $95,902.80. Following the completion of the transaction, the insider owned 13,955 shares in the company, valued at approximately $1,950,909. The trade was a 4.69% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 7.00% of the company's stock.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.